

PRESS RELEASE

AnalytiCon Discovery and Pharvaris extend their collaboration

AnalytiCon Discovery, a first-class provider of natural product, drug discovery and development services, today announced the extension of their research and development collaboration with Pharvaris, a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonist small molecules to patients.

AnalytiCon Discovery, a leader in the design and development of chiral compound libraries, has earned a strong reputation over the years as a drug discovery CRO in a wide range of collaborations. A key success story comes from its partnership with Pharvaris, a clinical-stage company specializing in the development of bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications.

Pharvaris has initiated Phase 2 studies of a bradykinin-B2-receptor antagonist for both on-demand and prophylactic treatment of HAE. With the extension of this collaboration for an additional 18 months, AnalytiCon Discovery and Pharvaris will continue to work together on the research and development of new bradykinin-B2-receptor antagonists to treat HAE and other conditions.

Jochen Knolle, Ph.D., chief scientific officer of Pharvaris, said “We are thrilled that our collaboration with AnalytiCon Discovery has been extended. They have been our research partner from Pharvaris’ inception and will continue to be instrumental in our drug discovery efforts on the development of new bradykinin-B2-receptor antagonists with the potential to treat additional indications.”

Potsdam
Germany
2 February 2022

AnalytiCon Discovery GmbH

Hermannswerder Haus 17
14473 Potsdam, Germany
www.ac-discovery.com

Contact

Dr. Lars Ole Haustedt
Vice President
Projects and Innovation
Tel.: +49 175 560 2427
l.haustedt@ac-discovery.com

AnalytiCon Discovery, LLC

15800 Crabbs Branch Way
Suite 300
Rockville, MD 20855, USA

Contact

Dr. Dietmar Wolf
Chief Business Officer
Tel.: +1 240654 7575
d.wolf@ac-discovery.com

Christoph Gibson, Vice President Drug Discovery and Development at AnalytiCon Discovery, said: "We are pleased to extend our fruitful collaboration with Pharvaris focussing on the characterization and development of new bradykinin-B2-receptor antagonists. This will open up new therapeutic indications for this highly attractive drug target."

Lutz Müller-Kuhrt, chief executive officer of AnalytiCon Discovery, adds: "The collaboration between AnalytiCon Discovery and Pharvaris is an excellent example of a synergistic partnership between early-stage drug discovery and development experts to advance therapies efficiently in clinical development."

About AnalytiCon

AnalytiCon Discovery provides drug discovery and development services. The technology platform builds on an extensive reservoir of synthetic and natural compounds and is complemented by a first-class drug discovery and development team. AnalytiCon's expertise also includes the identification and development of novel ingredients for the cosmetic and food industries. AnalytiCon has been a member of the BRAIN Group since 2013.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of AnalytiCon Discovery and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at AnalytiCon Discovery. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. AnalytiCon Discovery does not undertake any obligation to update or revise any forward-looking statements.